Sex differences in semaglutide muscle loss

A study published in Diabetes on 2 July 2026 reports that female ob/ob mice are completely resistant to semaglutide-induced skeletal muscle loss, while their male counterparts are not^[1]. The finding adds a sex-specific dimension to a growing conversation about muscle wasting during GLP-1 receptor agonist therapy.

What the study did and found

Researchers from the University of Utah, led by Ran Hee Choi, used ob/ob mice, a strain that carries a mutation in the leptin gene and becomes severely obese. Standard C57BL/6J female mice were not used because they are relatively resistant to diet-induced weight gain, which would have made it harder to study weight-loss effects. The ob/ob model allowed both sexes to start from a comparable obese baseline.

Both male and female ob/ob mice received semaglutide treatment. Body weight fell in both groups. The key divergence appeared in the skeletal muscle: male mice lost measurable muscle mass and strength, while female mice did not. The authors describe female mice as "completely resistant" to the semaglutide-induced muscle loss seen in males^[1]. The study concludes that semaglutide exerts sex-specific effects on muscle, and calls for investigation of the molecular mechanisms underlying that difference.

Why this matters: the muscle-loss backdrop

Weight lost on GLP-1 receptor agonists is not all fat. Clinical evidence shows that a meaningful portion of total weight reduction comes from lean tissue. A 2026 meta-analysis of seven randomised controlled trials (n=821) found that patients on GLP-1 receptor agonists at obesity-management doses lost an average of 1.74 kg of lean mass in absolute terms, with semaglutide-treated participants losing approximately 5.44 kg^[2]. Because fat and lean tissue are both reduced, authors note the proportional composition of the remaining body actually improves, but the absolute muscle loss is real and clinically relevant for older patients or those with existing sarcopenia.

A parallel line of preclinical research published in June 2026 found that co-administering ketone esters with semaglutide preserved skeletal muscle mass and function in obese mice without compromising fat loss^[3]. The University of Utah finding now adds a different angle: sex itself appears to be a protective variable, at least in this preclinical model.

What we do not yet know

Several questions remain open after this study. First, the mechanism: the authors identify sex-specific effects but have not yet characterised which hormonal, receptor-level, or metabolic pathways explain why female ob/ob muscle is protected. Second, translation to humans: ob/ob mice lack functional leptin, which shapes how their muscle responds to metabolic stress in ways that do not map cleanly onto human physiology. Third, the clinical literature on semaglutide and body composition comes predominantly from mixed-sex populations, and most published trials do not report lean-mass outcomes stratified by sex. Whether female patients on semaglutide lose proportionally less muscle than male patients is not yet established in human data.

A 2026 review on lean mass preservation strategies during GLP-1 therapy notes that measured lean mass on DXA or impedance scans does not always track closely with functional muscle performance^[4]. That distinction matters when interpreting both the rodent finding and the clinical meta-analysis: grip strength and muscle function are different endpoints from lean-mass kilograms, and a study confirming sex differences in functional outcomes alongside mass outcomes would carry more weight.

What this study is not

It is not human evidence. It is not a reason to assume female patients on semaglutide are automatically protected from lean-mass decline. It is not a finding that changes current clinical recommendations. The study is a well-designed preclinical signal that motivates further mechanistic and clinical work. The sex-specific finding is notable precisely because the broader clinical literature has not systematically addressed this question, making the ob/ob mouse data a useful flag rather than a conclusion.

Where this fits in the current research landscape

Three threads are converging in the semaglutide-and-muscle literature in 2026. The first is characterising the size of lean-mass loss in human trials. The second is identifying co-interventions, such as resistance exercise, adequate protein intake, and experimental pharmacological strategies, that can preserve muscle during weight reduction. The third, opened by this paper, is understanding whether patient characteristics including sex modify the muscle-loss response. A clinician following all three threads would take the ob/ob finding as a hypothesis-generating signal about sex differences, not as reassurance for female patients or a basis for changing prescribing practice.

The evidence-based steps for patients today remain resistance training and protein-adequate nutrition, regardless of sex. See our semaglutide overview for a full summary of the clinical evidence, and also the related explainer on 15-PGDH and muscle loss on GLP-1 drugs. Talk to a healthcare provider about a muscle-preservation plan suited to your individual circumstances.